GlassScriptPhysician profile
Avinash R Beeram
NPI 1477086056
$3,737.42
in general payments reported to CMS, 2019-2025
16 companies · $428 in 2025
The $428 reported for 2025 was more than what 90% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,844 · 2023: $1,371 · 2024: $94.16 · 2025: $428.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,894.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,893.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,556.93 | 2022 | |
| Abbott Laboratories | $919.11 | 2023 | Proclaim, Axium |
| Takeda Pharmaceuticals U.S.A., INC. | $198.08 | 2023-2025 | Entyvio, Gattex |
| Averitas Pharma INC. | $169.45 | 2023 | |
| Si-Bone, INC. | $150.15 | 2022 | |
| Janssen Biotech, INC. | $145.04 | 2023-2025 | Stelara, Tremfya |
| Spr Therapeutics, INC | $136.80 | 2022 | |
| Nevro Corp. | $124.71 | 2023 | Senza |
| Abbvie INC. | $116.98 | 2025 | |
| Merck Sharp & Dohme LLC | $57.63 | 2023-2025 | Bridion |
| Madrigal Pharmaceuticals | $34.72 | 2025 | Rezdiffra |
| Ironwood Pharmaceuticals, INC | $29.31 | 2023 | Linzess |
| Celltrion USA INC. | $28.04 | 2025 | Vegzelma |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.66 | 2024 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $24.23 | 2025 | Voquezna |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $21.58 | 2025 | Dupixent |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Avinash Beeram listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.